A comprehensive view of Inhalers / Sprays / Vaporizers. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer packaged goods (CPG) Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
Johnson & Johnson seeks FDA approval for SPRAVATO® as monotherapy for adults with treatment-resistant depression; nearly 30% of 280 million MDD patients have TRD, company cites Phase 4 study results
Published:
July 22, 2024
by Johnson & Johnson Services Inc.
|
Johnson & Johnson seeks FDA approval for SPRAVATO® as monotherapy for treatment-resistant depression; submission based on Phase 4 data showing rapid depressive symptom improvement within 24 hours
Published:
July 22, 2024
by Janssen Pharmaceutical Companies
|
FDA denies Orexo's OX124 nasal spray for opioid overdose for second time in 15 months; FDA requests additional technical data and human factor study results
Published:
July 17, 2024
by FiercePharma
|
U.S. Clinical Trial: University of Nebraska Listed a New Clinical Trial to Study Theophylline Nasal Spray for PD-Related Hyposmia and Anosmia
Published:
July 15, 2024
by Contify Life Science News
|
NIHR: Over-the-counter nasal sprays proven to keep colds and flu at bay and reduce antibiotic use
Published:
July 12, 2024
by Contify Life Science News
|
Ask us about our Consumer packaged goods (CPG) market view
Trending Chart
Interactive chart with headline count